Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)

NCT03585517 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

AML

Interventions

DRUG: IM23

Sponsor

Beijing Immunochina Medical Science & Technology Co., Ltd.